SPINELLA, AMELIA
 Distribuzione geografica
Continente #
NA - Nord America 12.429
AS - Asia 6.177
EU - Europa 4.870
SA - Sud America 886
Continente sconosciuto - Info sul continente non disponibili 242
AF - Africa 176
OC - Oceania 25
Totale 24.805
Nazione #
US - Stati Uniti d'America 11.957
SG - Singapore 1.829
IT - Italia 1.543
CN - Cina 1.488
GB - Regno Unito 959
HK - Hong Kong 679
BR - Brasile 674
VN - Vietnam 637
SE - Svezia 499
BD - Bangladesh 432
DE - Germania 417
RU - Federazione Russa 302
FR - Francia 260
FI - Finlandia 259
CA - Canada 230
KR - Corea 217
IN - India 205
ID - Indonesia 139
TR - Turchia 124
UA - Ucraina 105
NL - Olanda 84
MX - Messico 83
AR - Argentina 78
BG - Bulgaria 76
JP - Giappone 71
ES - Italia 69
ZA - Sudafrica 54
PL - Polonia 52
PK - Pakistan 46
IQ - Iraq 39
IL - Israele 36
AT - Austria 35
CO - Colombia 35
MY - Malesia 33
IE - Irlanda 32
CR - Costa Rica 31
LT - Lituania 27
AE - Emirati Arabi Uniti 26
MA - Marocco 25
AU - Australia 23
CL - Cile 23
BE - Belgio 22
CZ - Repubblica Ceca 21
EC - Ecuador 21
EG - Egitto 19
VE - Venezuela 19
RO - Romania 18
GT - Guatemala 17
SA - Arabia Saudita 16
TN - Tunisia 16
IR - Iran 15
PR - Porto Rico 15
SC - Seychelles 15
SV - El Salvador 15
CW - ???statistics.table.value.countryCode.CW??? 14
HN - Honduras 14
PE - Perù 14
NP - Nepal 13
UZ - Uzbekistan 13
AL - Albania 12
JO - Giordania 12
PH - Filippine 12
TH - Thailandia 12
TT - Trinidad e Tobago 12
TW - Taiwan 12
KE - Kenya 11
AZ - Azerbaigian 10
RS - Serbia 10
GP - Guadalupe 9
NI - Nicaragua 9
OM - Oman 9
EU - Europa 8
JM - Giamaica 8
PT - Portogallo 8
PY - Paraguay 8
DZ - Algeria 7
EE - Estonia 7
GR - Grecia 7
NG - Nigeria 7
PS - Palestinian Territory 7
BY - Bielorussia 6
BZ - Belize 6
DK - Danimarca 6
HU - Ungheria 6
UY - Uruguay 6
BB - Barbados 5
BH - Bahrain 5
CH - Svizzera 5
DO - Repubblica Dominicana 5
KG - Kirghizistan 5
SY - Repubblica araba siriana 5
AM - Armenia 4
ET - Etiopia 4
HR - Croazia 4
LU - Lussemburgo 4
SK - Slovacchia (Repubblica Slovacca) 4
AO - Angola 3
BO - Bolivia 3
BS - Bahamas 3
CG - Congo 3
Totale 24.519
Città #
Ashburn 1.510
Santa Clara 1.231
Singapore 1.135
San Jose 911
Council Bluffs 673
Fairfield 670
Hong Kong 668
Chandler 592
Southend 470
Hefei 439
Woodbridge 322
Houston 318
Seattle 279
Nyköping 266
London 255
Beijing 236
New York 225
Wilmington 224
Los Angeles 219
Cambridge 202
Ho Chi Minh City 199
Helsinki 192
Seoul 192
The Dalles 166
Hanoi 164
Milan 158
Chicago 151
Jacksonville 149
Ann Arbor 140
Dearborn 133
Bologna 127
San Diego 127
Modena 120
Jakarta 111
Buffalo 92
Lauterbourg 85
São Paulo 82
Princeton 75
Sofia 74
Munich 70
Atlanta 69
Bremen 69
Dallas 69
Shanghai 69
Orem 66
Moscow 59
Rome 59
Frankfurt am Main 53
Tokyo 53
Izmir 52
Denver 50
Toronto 47
Columbus 46
Montreal 46
Phoenix 44
Warsaw 43
Salt Lake City 42
Florence 41
Naples 41
Boardman 37
Parma 37
Johannesburg 35
Mexico City 33
Redwood City 32
Reggio Emilia 32
Brooklyn 31
Poplar 30
Chennai 29
Turku 29
Eugene 28
Guangzhou 28
Haiphong 28
New Delhi 28
Stockholm 28
Amsterdam 26
Da Nang 26
San Francisco 26
North Bergen 25
Ovada 25
San José 25
Kent 24
Lappeenranta 24
Ottawa 24
Delhi 23
Mumbai 22
Nuremberg 22
Philadelphia 22
Hillsboro 21
Palermo 21
Paris 21
Portsmouth 21
Redondo Beach 21
Turin 21
Vancouver 21
Washington 21
Rio de Janeiro 19
Brussels 18
Charlotte 18
Dublin 18
Ankara 17
Totale 15.507
Nome #
Systemic sclerosis progression INvestiGation (SPRING) Italian registry: Demographic and clinico-serological features of the scleroderma spectrum 462
Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients' population and review of the literature 378
COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series 376
Cryoglobulin evaluation: analysis of intra-laboratory and inter-laboratory variability 369
Established coronary artery disease in systemic sclerosis compared to type 2 diabetic female patients: a cross-sectional study 363
Cardiac involvement in systemic sclerosis: identification of high-risk patient profiles in different patterns of clinical presentation 362
Cardio-pulmonary disease management in patients with systemic sclerosis: cardio-rheumatology clinic and patient care standardisation proposal 359
Elevated Troponin Serum Levels in Adult Onset Still's Disease 355
Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature 355
Unusual association between Budd–Chiari syndrome secondary to antiphospholipid syndrome and relapsing polychondritis: a case report and review of the literature 350
Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report 344
Serum 25-OH vitamin D levels in systemic sclerosis: analysis of 140 patients and review of the literature 342
Ultrasonography involvement of carotid, upper and lower limb arteries in a large cohort of systemic sclerosis patients 340
The discrepancy between clinical and ultrasonographic remission in rheumatoid arthritis is not related to therapy or autoantibody status. 332
Long-term treatment with rituximab in interstitial lung disease related to systemic sclerosis: our clinical experience 326
CLINICAL AND PATHOLOGICAL FEATURES OF BREAST CANCER IN PATIENTS WITH SYSTEMIC SCLEROSIS: PRELIMINARY DATA FROM THE SCLERO-BREAST STUDY 317
Large Vessel Vasculitis Occurring in Rheumatoid Arthritis Patient under Anti-TNF Therapy 313
Management of cardiopulmonary disease in patients with systemic sclerosis: cardiorheumatology clinic and patient care standardization proposal 304
UNCLASSIFIABLE INTERSTITIAL LUNG DISEASE OR UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE? A CHALLENGING DIFFERENTIAL DIAGNOSIS 294
Use of Neem oil and Hypericum perforatum for treatment of calcinosis-related skin ulcers in systemic sclerosis 292
Advanced oxidation protein products in serum of patients with systemic sclerosis: a possible indicator of clinical evolution 289
Beyond cat scratch disease: a case report of bartonella infection mimicking vasculitic disorder 288
Photobiomodulation Therapy: A New Light in the Treatment of Systemic Sclerosis Skin Ulcers 284
The safety of iloprost in systemic sclerosis in a real-life experience 283
Autologous Fat Grafting for the Oral and Digital Complications of Systemic Sclerosis: Results of a Prospective Study 282
Assessing hand grasp in patients with systemic sclerosis using the 16-grasp test: Preliminary results from a multidisciplinary study group 281
DIGITAL NECROSIS IN SYSTEMIC SCLEROSIS NOT ONLY A MICROVASCULAR DISEASE: A CASE REPORT 278
INTERSTITIAL LUNG DISEASE IS ASSOCIATED TO INFECTIONS OF LOWER RESPIRATORY TRACT IN IMMUNOCOMPROMISED RHEUMATOID ARTHRITIS PATIENTS 273
Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study 270
The prevalence of asymptomatic early sacroiliitis in Crohn’s disease patients: The single experience of an Italian tertiary care centre 269
SEVERE VITAMIN D DEFICIENCY IN SYSTEMIC SCLEROSIS 268
Autologous fat grafting in the treatment of a scleroderma stump-skin ulcer: a case report 263
DANCE CLASS DEDICATED TO SCLERODERMA PATIENTS: JOINT EVALUATION, FUNCTIONAL AND QUALITY OF LIFE BEFORE AND AFTER TREATMENT – CLINICAL TRIAL 258
The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts 258
Procedural pain management in the treatment of scleroderma digital ulcers 251
AB0611 STRAIN ANALYSIS OF THE RIGHT VENTRICLE USING 2D-SPECKLE TRACKING ECHOCARDIOGRAPHY IN A COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS 251
NATURAL HISTORY OF CRYOGLOBULINEMIA FROM 2000 TO 2018 FROM THE LABORATORY POINT OF VIEW: AN ANALYSIS OF CRYOGLOBULIN CHARACTERISTICS IN A SINGLE CENTER. 241
PREVALENCE OF ULTRASOUND ABNORMALITIES IN PATIENTS WITH PSORIATIC ARTHRITIS IN A CLINICAL PHASE OF MINIMAL DISEASE ACTIVITY UNDER ANTI-TNF TREATMENT 240
Thu0349 autologous fat grafting in the treatment of patients with systemic sclerosis: current experience and future prospects 240
Invited Response on: Comments on "Autologous Fat Grafting for the Oral and Digital Complications of Systemic Sclerosis: Results of a Prospective Study" 238
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study 236
Peripheral Microangiopathy Changes in Pulmonary Arterial Hypertension Related to Systemic Sclerosis: Data From a Multicenter Observational Study 235
Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study 234
Promising use of filgotinib in patients affected by systemic sclerosis: Preliminary data from a case series of 5 patients 234
Erratum: Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature (Journal of Thoracic Disease (2019) 11 (1621-1628) DOI: 10.21037/jtd.2019.03.28) 233
AB0645 CANNABINOIDS IN THE TREATMENT OF PAIN RELATED TO SYSTEMIC SCLEROSIS SKIN ULCERS: OUR EXPERIENCE 233
AB0724 Cardio-pulmonary disease management in patients with systemic sclerosis: cardio-rheumatology clinic and patient care standardisation proposal 230
The predictive role of the TAPSE/sPAP ratio for cardiovascular events and mortality in systemic sclerosis with pulmonary hypertension 229
Altered pathways of keratinization, extracellular matrix generation, angiogenesis, and stromal stem cells proliferation in patients with systemic sclerosis 229
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups 228
IS THERE A DISSOCIATION BETWEEN CLINICAL REMISSION AND ULTRASONOGRAPHIC ASSESSMENT IN RHEUMATOID ARTHRITIS? 222
Management of Systemic Sclerosis Patients in the COVID-19 Era: The Experience of an Expert Specialist Reference Center 222
Pulmonary arterial hypertension: Guidelines and unmet clinical needs 222
One-year clinical experience on the use of Nintedanib in Systemic Sclerosis 220
COVID-19 in Italian patients with rheumatic autoimmune systemic diseases 218
ORAL MANIFESTATIONS IN SYSTEMICSCLEROSIS: CLINICAL EVALUATION OF APERSONAL CASE SERIES OF 13 SCLERODERMAPATIENTS 216
AB0760 Advanced oxidation protein products in serum of patients with systemic sclerosis: a possible indicator of clinical evolution 216
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments 216
Cryofibrinogen: A possibile risk factor in systemic sclerosis 211
Impegno cardiaco nella sclerosi sistemica 210
Living with arthritis: a “training camp” for coping with stressful events? A survey on resilience of arthritis patients following the COVID-19 pandemic 210
Role of COVID-19 in the progression of scleroderma interstitial lung disease and new onset pulmonary hypertension: a challenging case report. 207
Systemic sclerosis cutaneous expression: Management of skin fibrosis and digital ulcers 206
EFFICACY OF CERTOLIZUMAB PEGOL FOR DISEASE CONTROL OF PATIENTS AFFECTED BY ENTEROPATHIC SPONDYLARTHRITIS FOLLOWED BY THE JOINT GASTRO-RHEUMATOLOGICAL CLINIC 204
Cryoproteinemia: new frontiers for clinicians and the laboratory 203
AB0212 LONG-TERM TREATMENT WITH RITUXIMAB IN SYSTEMIC SCLEROSISMANAGEMENT: AN OVERVIEW OF THE CLINICAL EXPERIENCE FROM A REAL-LIFE SETTING 202
A CALL FOR A COMPREHENSIVE ROLE DEFINITION OF THE STUDY COORDINATOR IN RHEUMATOLOGICAL CLINICAL STUDIES 201
A New Promising Role for Selexipag in the Treatment of Scleroderma Vasculopathy: Preliminary Results From a Third Level Italian Scleroderma Center 199
From Localized Scleroderma to Systemic Sclerosis: Coexistence or Possible Evolution 198
THU0600 a case of systemic sclerosis complicated by renal crisis: potential etiopathogenetic role of cytomegalovirus and treatment 192
THE PREDICTIVE ROLE OF THE TAPSE/sPAP RATIO FOR CARDIOVASCULAR EVENTS AND MORTALITY IN SYSTEMIC SCLEROSIS COMPLICATED BY PULMONARY HYPERTENSION 191
ACCERTAMENTO DELLA DISABILITÀ NELLE MALATTIE REUMATOLOGICHE (EX L.R. N.4 DEL 19 FEBBRAIO 2008) PROPOSTA DI PROTOCOLLO ORGANIZZATIVO 187
POS0837 THE USE OF CANNABIDIOL IN THE TREATMENT OF PAIN RELATED TO SCLERODERMA DIGITAL ULCERS 186
Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology 186
Letters to the Editors 185
Secondary cryofbrinogenemia is related to more severe microangiopathic involvement in systemic sclerosis: results from a retrospective observational study 184
PROBABILITÀ DI SIEROCONVERSIONE DEL TEST QUANTIFERON DURANTE LA TERAPIA BIOTECNOLOGICA: DATI PRELIMINARI DI UNO STUDIO RETROSPETTIVO CONDOTTO PRESSO L’ARTHRITIS CLINIC DELL’AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA 183
Long-term retention rate, adverse event temporal patterns and rescue treatment strategies of mycophenolate mofetil in systemic sclerosis: insights from real-life 181
Secondary cryofibrinogenemia is related to more severe microangiopathic involvement in systemic sclerosis: results from a retrospective observational study. 177
Organic-inorganic materials through first simultaneous frontal polymerization and frontal geopolymerization 176
SAT0285 EVALUATION OF CHRONIC PAIN IN PATIENTS WITH SYSTEMIC SCLEROSIS COMPARED TO THOSE WITH CHRONIC HEADACHE AND RHEUMATOID ARTHRITIS 172
Resilience of systemic sclerosis patients following the first COVID-19 wave in Italy 171
JANUS KINASES INHIBITORS IN CLINICAL PRACTICE IN ITALY. RESULTS FROM A SINGLE CENTER EXPERIENCE 170
Covid-19 vaccine hesitancy in systemic sclerosis 168
Real life use of prostacyclin analog (Iloprost), a multi-centric survey data from the scleroderma study group Emilia Romagna (Sclero-RER) and review of the literature 166
Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study 164
Erratum: Unusual association between Budd-Chiari syndrome secondary to antiphospholipid syndrome and relapsing polychondritis: A case report and review of the literature (Clinical Rheumatology (2013) 32 (905-907) DOI: 10.1007/s10067-013-2229-z) 164
Clinical and ultrasonographic predictors of disease activity after TNF-α inhibitor spacing in patients with psoriatic arthritis 163
FRI0442 Long-term treatment with rituximab in interstitial lung disease related to systemic sclerosis: our clinical experience 158
MYCOPHENOLATE MOFETIL TREATMENT REDUCES THE RISK OF TREATMENT ESCALATION DUE TO VASCULAR COMPLICATIONS IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: EMULATION OF A TARGET TRIAL FROM ITALIAN RHEUMATOLOGY SOCIETY SPRING REGISTRY 156
BMP-4 and fetuin A in systemic sclerosis patients with or without calcinosis 153
Erratum: From Localized Scleroderma to Systemic Sclerosis: Coexistence or Possible Evolution (Dermatology Research and Practice (2018) 2018 (1284687) DOI: 10.1155/2018/1284687) 152
L’IPERTENSIONE POLMONARE: DALLE NUOVE LINEE GUIDA ALLA PRATICA CLINICA 149
OP0063 QUANTITATIVE COMPUTED TOMOGRAPHY PREDICTS 10-YEAR MORTALITY IN INTERSTITIAL LUNG DISEASE RELATED TO SYSTEMIC SCLEROSI 138
Infections of scleroderma digital ulcers: A single center cohort retrospective study 137
Pulmonary Arterial Hypertension Incidence in Patients With Systemic Sclerosis Treated With Bosentan for Digital Ulcers: Evidence From the SPRING-SIR Registry. 131
Significant nailfold capillary loss and late capillaroscopic pattern are associated with pulmonary arterial hypertension in systemic sclerosis 124
Prevalence and clinical relevance of digital ulcers in systemic sclerosis patients from the real-life: the experience of the SPRING Registry of the Italian Society for Rheumatology 124
First-line diagnostic tests to intercept primary heart involvement in systemic sclerosis: Clinical associations from the SPRING-SIR registry 123
From Raynaud Phenomenon to Systemic Sclerosis in COVID-19: A Case Report 122
Totale 23.595
Categoria #
all - tutte 98.254
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 98.254


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.179 0 0 0 0 75 130 45 108 175 136 326 184
2022/20231.671 216 207 116 147 205 210 69 151 220 25 53 52
2023/20241.162 42 69 52 168 204 91 91 111 31 40 98 165
2024/20254.633 139 77 91 311 851 734 369 268 532 215 413 633
2025/20269.328 618 317 633 1.104 1.366 622 1.130 435 853 890 816 544
2026/20272.994 326 616 571 1.213 268 0 0 0 0 0 0 0
Totale 24.805